Overview
Aicardi syndrome is a rare neurodevelopmental disorder that occurs almost exclusively in females and is characterized by a classic triad of features: agenesis (partial or complete absence) of the corpus callosum, infantile spasms (a type of seizure), and distinctive chorioretinal lacunae (lesions in the light-sensitive tissue at the back of the eye). The condition is thought to result from a de novo mutation on the X chromosome, and it is believed to be lethal in males, which explains why nearly all affected individuals are female, with rare exceptions in males with Klinefelter syndrome (47,XXY). The specific causative gene has not yet been identified. Aicardi syndrome primarily affects the brain, eyes, and skeletal system. In addition to the classic triad, affected individuals frequently exhibit other brain malformations such as cortical heterotopias, polymicrogyria, and intracranial cysts (including choroid plexus papillomas). Ocular abnormalities may include microphthalmia, optic nerve colobomas, and optic disc anomalies. Skeletal features can include costovertebral anomalies such as hemivertebrae and absent or fused ribs. Intellectual disability is typically severe, and epilepsy is often refractory to standard antiepileptic medications. Some individuals may also develop skin lesions. There is currently no cure for Aicardi syndrome, and treatment is primarily supportive and symptomatic. Management focuses on seizure control, which can be challenging and may require multiple antiepileptic drugs, dietary therapies such as the ketogenic diet, or in some cases surgical interventions. Physical therapy, occupational therapy, and early intervention programs are important to optimize developmental outcomes. Regular ophthalmologic and neurological follow-up is essential. Prognosis varies considerably, but many individuals survive into childhood and adolescence, with some living into adulthood, though significant neurodevelopmental impairment is typical.
Clinical phenotype terms— hover any for plain English:
X-linked dominant
Carried on the X chromosome; a single copy can cause the condition
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventBaylor College of Medicine
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Aicardi syndrome.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Aicardi syndrome.
Community
No community posts yet. Be the first to share your experience with Aicardi syndrome.
Start the conversation →Latest news about Aicardi syndrome
No recent news articles for Aicardi syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Aicardi syndrome
What is Aicardi syndrome?
Aicardi syndrome is a rare neurodevelopmental disorder that occurs almost exclusively in females and is characterized by a classic triad of features: agenesis (partial or complete absence) of the corpus callosum, infantile spasms (a type of seizure), and distinctive chorioretinal lacunae (lesions in the light-sensitive tissue at the back of the eye). The condition is thought to result from a de novo mutation on the X chromosome, and it is believed to be lethal in males, which explains why nearly all affected individuals are female, with rare exceptions in males with Klinefelter syndrome (47,XX
How is Aicardi syndrome inherited?
Aicardi syndrome follows a x-linked dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Aicardi syndrome typically begin?
Typical onset of Aicardi syndrome is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Aicardi syndrome?
Yes — 1 recruiting clinical trial is currently listed for Aicardi syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Aicardi syndrome?
20 specialists and care centers treating Aicardi syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.